scPharmaceuticals Inc. (SCPH)

4,3300 +0,3700 (+9,34%) A partir del 03:08PM EDT. Mercado abierto.

scPharmaceuticals Inc.

25 Mall Road
Suite 203
Burlington, MA 01803
United States
617 517 0730
https://www.scpharmaceuticals.com

Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 135

Ejecutivos clave

Nombre	Título	Paga	Ejecutado	Año de nacimiento
Mr. John H. Tucker	President, CEO, Principal Executive Officer & Director	981,56k	N/A	1963
Ms. Rachael Nokes	Chief Financial Officer	573,8k	N/A	1975
Mr. Michael D. Hassman	Senior Vice President of Technical Operations	N/A	N/A	N/A
Katherine Taudvin	Vice President of Corporate Affairs & Human Resources	N/A	N/A	N/A
Dr. John Mohr Pharm.D.	Senior Vice President of Clinical Development & Medical Affairs	N/A	N/A	N/A
Steve Parsons	Senior Vice President of Commercial	N/A	N/A	N/A

Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.

Gobierno corporativo

El ISS Governance QualityScore de scPharmaceuticals Inc., a día 1 de junio de 2024, es 7. Las puntuaciones base son Auditoría: 5; Tablero: 7; Derechos de los accionistas: 8; Compensación: 8.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.